COMPANY PROFILE

Ability Biologics

Explore full profile

Developing innovative targeted immuno therapeutics to addressing unmet medical needs for cancer and autoimmune diseases

Montreal, CanadaFounded 2023Biotech & Life Sciences

Valuation $50–100M Last recorded · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Ability Biologics

Ability.bio is a biotechnology company focused on developing highly specific and selective antibody therapeutics to address significant unmet medical needs. The company operates in the biopharmaceutical market, leveraging its proprietary discovery platform to generate logic-enabled antibodies that interact with key immune pathways. Ability.bio serves clients in the healthcare and pharmaceutical sectors, including research institutions and clinical laboratories. The business model revolves around the discovery, development, and licensing of therapeutic antibodies, generating revenue through partnerships, licensing deals, and potential future product sales. The company is guided by seasoned investors and led by experienced professionals with deep expertise in R&D and business operations.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2023
Headquarters: Montreal, Canada
Employees: 25
Open positions: None listed
Dealroom signal: 52.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SEED✓Equity / VC	Jun 2024	$18M	$60M	Seido Capital · Invest Quebec · Fonds de solidarité FTQ · Charles River Laboratories International	↗
SEED✓Equity / VC	Dec 2023	$12M	$48M	Amplitude Ventures	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Ability Biologics website traffic

Latest recorded traffic for Ability Biologics is 3.7K monthly website visits, up 146.7% over the last three months. Ability Biologics's team declined 3.8% over the past year.

Latest monthly visits3.7K 3-month web change+146.7% 1-year team growth-3.8%

Monthly website visitsDec 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TITrueBinding (formally Immutics)An early-stage biotherapeutics development company focused on creating new and exciting molecules for applications	Foster City, United States	Operational	36	$327M	$500M
GLGemina LabsDeveloped and patented a transformative bio-chemistry that powers next-generation testing platforms for detecting a wide range of pathogens that affect humans and animals	Calgary, Canada	Operational
LYLyopor3D collagen scaffold for 3D cell culture, suitable for testing the behavior of a wide range of cells in their natural 3D environment	Brno, Czechia	Operational
ETEvergreen TheragnosticsContract development and manufacturing of therapeutic radiopharmaceuticals	Jersey City, United States	Acquired
NDNuGen Medical DevicesAn emerging specialty medical device company focused on developing and commercializing novel drug delivery technologies	Toronto, Canada	Operational
ABAC BioscienceA clinical stage biotech company focused on novel approaches to provide more effective treatments for solid tumor cancer patients	Ecublens, Switzerland	Operational
STSapreme TechnologieDevelops new technologies within the field of macromolecule therapeutics such as antibody-drug conjugates and oligonucleotide-based therapeutics	Driebergen-Rijsenburg, Netherlands	Operational
CECerecinHealthcare company that develops a novel evidence-based therapeutics, and products that aim to help people	Denver, United States	Operational